Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/22/2025

Antibiotic Selection for Dual Coverage of Staph aureus and E. coli

Empiric Single-Agent Options

  • The Infectious Diseases Society of America recommends cefazolin as a first-generation cephalosporin that provides good coverage for MSSA and most community-acquired E. coli 1
  • For serious MSSA infections, the American Heart Association suggests that penicillinase-resistant penicillins are the drugs of choice, and first-generation cephalosporins are effective alternatives 1

Methicillin-Susceptible S. aureus (MSSA) Considerations

  • The European Society of Cardiology states that beta-lactam agents, such as nafcillin, oxacillin, cefazolin, or piperacillin-tazobactam, are the preferred treatment for MSSA infections, as they are superior to vancomycin 2
  • Clindamycin 600 mg IV/PO three times daily can be used as an alternative for MSSA treatment if local resistance is less than 10% 1

Methicillin-Resistant S. aureus (MRSA) Considerations

  • The Journal of Microbiology, Immunology and Infection recommends vancomycin 30-60 mg/kg/day IV in 2-4 divided doses as the first-line treatment for serious MRSA infections 5
  • Linezolid 600 mg IV/PO every 12 hours is an alternative treatment for MRSA infections 5

E. coli Coverage

  • The Praxis Medical Insights guideline suggests that obtaining cultures and adjusting therapy based on susceptibility results is crucial for effective E. coli treatment 8

Clinical Approach Algorithm

  • The Clinical Infectious Diseases journal recommends determining methicillin susceptibility status and using beta-lactam agents for MSSA confirmed infections 1
  • For MRSA confirmed or suspected infections, vancomycin or linezolid should be added to E. coli coverage 5

Common Pitfalls to Avoid

  • The European Heart Journal warns against using vancomycin for MSSA when beta-lactams can be used, as vancomycin is inferior 2
  • The Praxis Medical Insights guideline advises against using tetracyclines in children under 8 years of age 5
  • Obtaining blood cultures before starting antibiotics is recommended if systemic symptoms are present 8